Pathophysiology and pharmacological treatment of insulin resistance.

Diabetes mellitus type 2 is a world-wide growing health problem affecting more than 150 million people at the beginning of the new millennium. It is believed that this number will double in the next 25 yr. The pathophysiological hallmarks of type 2 diabetes mellitus consist of insulin resistance, pancreatic beta-cell dysfunction, and increased endogenous glucose production. To reduce the marked increase of cardiovascular mortality of type 2 diabetic subjects, optimal treatment aims at normalization of body weight, glycemia, blood pressure, and lipidemia. This review focuses on the pathophysiology and molecular pathogenesis of insulin resistance and on the capability of antihyperglycemic pharmacological agents to treat insulin resistance, i.e., a-glucosidase inhibitors, biguanides, thiazolidinediones, sulfonylureas, and insulin. Finally, a rational treatment approach is proposed based on the dynamic pathophysiological abnormalities of this highly heterogeneous and progressive disease.

[1]  J. Auwerx,et al.  Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat , 1997, Diabetes.

[2]  D. Giugliano,et al.  Pharmacokinetic-Pharmacodynamic Relationships of Acarbose , 1996, Clinical pharmacokinetics.

[3]  B. Seed.  PPARγ and colorectal carcinoma: Conflicts in a nuclear family , 1998, Nature Medicine.

[4]  L. Tartaglia,et al.  Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.

[5]  P. Raskin,et al.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. , 1998, The New England journal of medicine.

[6]  R. Kreisberg,et al.  Lactate Turnover and Gluconeogenesis in Obesity: Effect of Phenformin , 1970, Diabetes.

[7]  S. Lillioja,et al.  Linkage of Chromosomal Markers on 4q With a Putative Gene Determining Maximal Insulin Action in Pima Indians , 1993, Diabetes.

[8]  U. Garbin,et al.  Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers , 1997, Diabetologia.

[9]  C. Bailey,et al.  Sites of metformin-stimulated glucose metabolism. , 1990, Biochemical pharmacology.

[10]  P. Brunetti,et al.  Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone , 1993 .

[11]  R. Anderson,et al.  Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study , 1999, Diabetes, obesity & metabolism.

[12]  H. Beck-Nielsen,et al.  In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes. , 1988, Diabetes research.

[13]  W. J. Andrews,et al.  Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. , 1992, Diabetes research.

[14]  S. Haffner,et al.  Long-Term Titrated-Dose α-Glucosidase Inhibition in Non-Insulin-Requiring Hispanic NIDDM Patients , 1998, Diabetes Care.

[15]  G. Condorelli,et al.  NIDDM Associated With Mutation in Tyrosine Kinase Domain of Insulin Receptor Gene , 1992, Diabetes.

[16]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[17]  Melvin Prince,et al.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. , 1999, Diabetes care.

[18]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[19]  Kolterman Og.  Glyburide in non-insulin-dependent diabetes: an update. , 1992 .

[20]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[21]  J. Buse,et al.  Combining insulin and oral agents. , 2000, The American journal of medicine.

[22]  J. Gerich,et al.  The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. , 1998, Endocrine reviews.

[23]  R. Ferner,et al.  Impaired β-cell Responses Improve when Fasting Blood Glucose Concentration is Reduced in Non-insulin-dependent Diabetes , 1988 .

[24]  G. Müller,et al.  Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas. , 1995, Diabetes research and clinical practice.

[25]  H. Beck-Nielsen,et al.  Effects of sulfonylureas on adipocyte and skeletal muscle insulin action in patients with non-insulin-dependent diabetes mellitus. , 1991, The American journal of medicine.

[26]  L. Corbo,et al.  The potentiation of exogenous insulin by tolbutamide in depancreatized dogs. , 1957, The Journal of clinical investigation.

[27]  C. Kahn,et al.  Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein , 1991, Nature.

[28]  G. Ward,et al.  Gliclazide Therapy Is Associated with Potentiation of Postbinding Insulin Action in Obese, Non-insulin-dependent Diabetic Subjects , 1985, Diabetes.

[29]  J. Olefsky,et al.  Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. , 1988, The Journal of clinical investigation.

[30]  H. Häring,et al.  Amino acid polymorphism Gly 972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[31]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[32]  L. S. Hermann,et al.  Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study , 1994, Diabetes Care.

[33]  S. Elbein,et al.  Linkage Studies of NIDDM with 23 Chromosome 11 Markers in a Sample of Whites of Northern European Descent , 1996, Diabetes.

[34]  Lawrence A Leiter,et al.  Cellular Mechanism of Action of Metformin , 1990, Diabetes Care.

[35]  H. Lebovitz,et al.  Glipizide: A Second‐generation Sulfonylurea Hypoglycemic Agent; Pharmacology, Pharmacokinetics and Clinical Use , 1985, Pharmacotherapy.

[36]  R. Campbell.  Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus , 1998, The Annals of pharmacotherapy.

[37]  J. A. Scarlett,et al.  The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects , 1984, Diabetes.

[38]  Riddle Mc.  Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. , 1996 .

[39]  J. Amatruda,et al.  Potentiation of Insulin Action by a Sulfonylurea in Primary Cultures of Hepatocytes from Normal and Diabetic Rats , 1983, Diabetes.

[40]  U. Smith,et al.  Effects of Metformin and Metoprolol CR on Hormones and Fibrinolytic Variables during a Hyperinsulinemic, Euglycemic Clamp in Man , 1994, Thrombosis and Haemostasis.

[41]  P. Vollenweider,et al.  Body fat and sympathetic nerve activity in healthy subjects. , 1994, Circulation.

[42]  P. Heinke,et al.  A stimulatory effect of tolbutamide on the insulin-mediated glucose uptake in subjects with impaired glucose tolerance (IGT). , 2009, Experimental and clinical endocrinology.

[43]  H. Yki-Järvinen,et al.  Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. , 1988, The American journal of medicine.

[44]  N. Nurjhan,et al.  Insulin Dose-Response Characteristics for Suppression of Glycerol Release and Conversion to Glucose in Humans , 1986, Diabetes.

[45]  A. Consoli,et al.  Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.

[46]  G. Pagano,et al.  Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. , 1994, Diabete & metabolisme.

[47]  R. Holman,et al.  The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. , 1997, Metabolism: clinical and experimental.

[48]  R. Jung,et al.  Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy. , 1987, Clinical science.

[49]  J. Papp,et al.  Cardiovascular Effects of Conventional Sulfonylureas and Glimepiride , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[50]  M. Davidson,et al.  An overview of metformin in the treatment of type 2 diabetes mellitus. , 1997, The American journal of medicine.

[51]  G. Lienhard,et al.  The 60-kDa Phosphotyrosine Protein in Insulin-treated Adipocytes Is a New Member of the Insulin Receptor Substrate Family* , 1997, The Journal of Biological Chemistry.

[52]  David M Nathan,et al.  Some answers, more controversy, from UKPDS , 1998, The Lancet.

[53]  H. Klein,et al.  Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic subjects. , 1987, The Journal of clinical investigation.

[54]  D. Accili,et al.  The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. , 1999, The Journal of clinical investigation.

[55]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[56]  C. Bogardus,et al.  Insulin-sensitive tyrosine kinase: relationship with in vivo insulin action in humans. , 1990, The American journal of physiology.

[57]  C. Jung,et al.  Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes. , 1985, The Journal of biological chemistry.

[58]  J. Auwerx.  PPARγ, the ultimate thrifty gene , 1999, Diabetologia.

[59]  S. O’Rahilly,et al.  Detection of Mutations in Insulin-Receptor Gene in NIDDM Patients by Analysis of Single-Stranded Conformation Polymorphisms , 1991, Diabetes.

[60]  D L Rothman,et al.  Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. , 1996, The New England journal of medicine.

[61]  R. Hamman,et al.  The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus , 1985, Diabetes.

[62]  W. J. Andrews,et al.  Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal , 1984, Diabetes.

[63]  F. Giorgino,et al.  Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. , 1995, The Journal of clinical investigation.

[64]  P. Ferré,et al.  Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. , 1989, The Biochemical journal.

[65]  J. Gerich.  Sulfonylureas in the treatment of diabetes mellitus--1985. , 1985, Mayo Clinic proceedings.

[66]  M. Kasuga,et al.  Requirement of Atypical Protein Kinase Cλ for Insulin Stimulation of Glucose Uptake but Not for Akt Activation in 3T3-L1 Adipocytes , 1998, Molecular and Cellular Biology.

[67]  M. Hanefeld,et al.  Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone , 1991, Diabetes Care.

[68]  D. Finegood,et al.  The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. , 1996, The Journal of clinical endocrinology and metabolism.

[69]  Gerich Je,et al.  Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues , 1978 .

[70]  R. Andrade,et al.  Acarbose-associated hepatotoxicity. , 1998, Diabetes care.

[71]  C. Bogardus,et al.  Evidence for Linkage Between a Region on Chromosome 1p and the Acute Insulin Response in Pima Indians , 1995, Diabetes.

[72]  C. Spurr,et al.  Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone , 1998, Annals of Internal Medicine.

[73]  P. Herson,et al.  Leptin activates ATP‐sensitive potassium channels in the rat insulin‐secreting cell line, CRI‐G1 , 1997, The Journal of physiology.

[74]  C. Fox.  Diabetes and hypertension: an era of clarity or confusion? , 1999, Journal of Human Hypertension.

[75]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[76]  H. Klein,et al.  In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. , 1993, Endocrinology.

[77]  G. Mancia,et al.  Sympathetic activation in obese normotensive subjects. , 1995, Hypertension.

[78]  K. Johansen.  Efficacy of metformin in the treatment of NIDDM. Meta-analysis. , 1999, Diabetes care.

[79]  J. Girard,et al.  Troglitazone Inhibits Fatty Acid Oxidation and Esterification, and Gluconeogenesis in Isolated Hepatocytes from Starved Rats , 1996, Diabetes.

[80]  R. Bretzel,et al.  Leptin inhibition of insulin secretion from isolated human islets , 1997, Acta Diabetologica.

[81]  J. Selby,et al.  First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. , 1999, Diabetes care.

[82]  M. Byrne,et al.  Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. , 1997, The Journal of clinical investigation.

[83]  D. Peters,et al.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. , 1995, Drugs.

[84]  H. Häring,et al.  Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a PI3-kinase mediated effect , 1997, Diabetologia.

[85]  P. Fasching,et al.  Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. , 1991, Metabolism: clinical and experimental.

[86]  H. Shamoon,et al.  Oral Vanadyl Sulfate Improves Insulin Sensitivity in NIDDM but Not in Obese Nondiabetic Subjects , 1996, Diabetes.

[87]  J. Assal,et al.  Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. , 1985, The Journal of clinical endocrinology and metabolism.

[88]  M. Lazar,et al.  Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[89]  R. DeFronzo,et al.  The Disposal of an Oral Glucose Load in Healthy Subjects: A Quantitative Study , 1985, Diabetes.

[90]  Lawrence A Leiter,et al.  The Effect of Acarbose on Insulin Sensitivity in Subjects With Impaired Glucose Tolerance , 1996, Diabetes Care.

[91]  L. Rossetti,et al.  Mechanisms of fatty acid-induced inhibition of glucose uptake. , 1994, The Journal of clinical investigation.

[92]  N. Christensen,et al.  Metabolic and cardiovascular responses to epinephrine in diabetic autonomic neuropathy. , 1987, The New England journal of medicine.

[93]  G. A. Fleming,et al.  Lactic acidosis in patients with diabetes treated with metformin. , 1998, The New England journal of medicine.

[94]  R. Heine,et al.  Association of the insulin-receptor variant Met-985 with hyperglycemia and non-insulin-dependent diabetes mellitus in the Netherlands: a population-based study. , 1996, American journal of human genetics.

[95]  I. Campbell,et al.  One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. , 1994, Diabete & metabolisme.

[96]  C. Bailey,et al.  Importance of the intestine as a site of metformin‐stimulated glucose utilization , 1994, British journal of pharmacology.

[97]  E. Horton,et al.  Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes , 1998, Diabetes Care.

[98]  J. Proietto,et al.  Low-Dose Acarbose Improves Glycemic Control in NIDDM Patients Without Changes in Insulin Sensitivity , 1993, Diabetes Care.

[99]  D. Dills,et al.  Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[100]  P. Ravenscroft,et al.  Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. , 1991, Australian and New Zealand journal of medicine.

[101]  R. Goldberg,et al.  A Dose-Response Study of Glimepiride in Patients With NIDDM Who Have Previously Received Sulfonylurea Agents , 1996, Diabetes Care.

[102]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[103]  E. Diamanti-Kandarakis,et al.  Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. , 1998, European journal of endocrinology.

[104]  R. Prager,et al.  Effects of 8-Wk α-Glucosidase Inhibition on Metabolic Control, C-Peptide Secretion, Hepatic Glucose Output, and Peripheral Insulin Sensitivity in Poorly Controlled Type II Diabetic Patients , 1989, Diabetes Care.

[105]  R. Coniff,et al.  Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. , 1994, Archives of internal medicine.

[106]  C. Zancanaro,et al.  Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. , 1984, Diabete & metabolisme.

[107]  O. Pedersen,et al.  Gliclazide and insulin action in human muscle. , 1991, Diabetes research and clinical practice.

[108]  R. Wolfe,et al.  Metabolic interactions between glucose and fatty acids in humans. , 1998, The American journal of clinical nutrition.

[109]  S. G. Rains,et al.  The Effect of Glibenclamide and Metformin on Serum Lipoproteins in Type 2 Diabetes , 1988, Diabetic medicine : a journal of the British Diabetic Association.

[110]  C. Burant,et al.  Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.

[111]  N. York,et al.  Characterization of the Molecular Mode of Action of the Sulfonylurea, Glimepiride, at β-Cells , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[112]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[113]  L. Groop,et al.  Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. , 1994, The Journal of clinical investigation.

[114]  S. Rich,et al.  Linkage of Genetic Markers on Human Chromosomes 20 and 12 to NIDDM in Caucasian Sib Pairs With a History of Diabetic Nephropathy , 1997, Diabetes.

[115]  T. Linn,et al.  The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[116]  J. Jaspan,et al.  Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes , 1987, Diabetes.

[117]  R. Farese,et al.  Sulfonylurea-Stimulated Glucose Transport Association With Diacylglycerollike Activation of Protein Kinase C in BC3H1 Myocytes , 1990, Diabetes.

[118]  C. R. Kahn,et al.  Insulin Action, Diabetogenes, and the Cause of Type II Diabetes , 1994, Diabetes.

[119]  William Arbuthnot Sir Lane,et al.  Role of IRS-2 in insulin and cytokine signalling , 1995, Nature.

[120]  B. Ludvik,et al.  Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. , 1994, The New England journal of medicine.

[121]  R. DeFronzo,et al.  Mechanism of Improvement in Glucose Metabolism After Chronic Glyburide Therapy , 1984, Diabetes.

[122]  U. Keller,et al.  Sulfonylurea Therapy Fails to Diminish Insulin Resistance in Type I-Diabetic Subjects , 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[123]  R. Rosskamp,et al.  Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[124]  J. Feldman,et al.  Glyburide: A Second‐generation Sulfonylurea Hypoglycemic Agent , 1985, Pharmacotherapy.

[125]  C. R. Kahn,et al.  Genetics of non-insulin-dependent (type-II) diabetes mellitus. , 1996, Annual review of medicine.

[126]  G. Pagano,et al.  Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. , 1995, Diabete & metabolisme.

[127]  R. Henry,et al.  Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. , 1999, The Journal of clinical investigation.

[128]  P. Raskin,et al.  Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients , 1998 .

[129]  A. Krolewski,et al.  Exclusion of insulin receptor substrate 2 (IRS-2) as a major locus for early-onset autosomal dominant type 2 diabetes. , 1999, Diabetes.

[130]  H. Yki-Järvinen.  Pathogenesis of non-insulin-dependent diabetes mellitus , 1994, The Lancet.

[131]  J. Halaas,et al.  Leptin and the regulation of body weight in mammals , 1998, Nature.

[132]  L. Groop,et al.  Circulating TNF-alpha and Leptin Levels in Offspring of NIDDM Patients Do Not Correlate to Individual Insulin Sensitivity , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[133]  P. Vague,et al.  Fibrinogen, fibrinolysis and diabetes mellitus: a comment , 1997, Diabetologia.

[134]  B. Howard.  Insulin resistance and lipid metabolism. , 1999, The American journal of cardiology.

[135]  M. Birnbaum,et al.  1 Cellular insulin action and insulin resistance , 1993 .

[136]  O. Kolterman.  The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics. , 1987, Diabetes/metabolism reviews.

[137]  P. Raskin,et al.  Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[138]  A. Avogaro,et al.  Effect of Metformin on Insulin-Stimulated Glucose Turnover and Insulin Binding to Receptors in Type II Diabetes , 1987, Diabetes Care.

[139]  T. Fujiwara,et al.  Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL KsJ-db db mice , 1995 .

[140]  H. Klein,et al.  Association of Metformin's Effect to Increase Insulin-Stimulated Glucose Transport With Potentiation of Insulin-Induced Translocation of Glucose Transporters From Intracellular Pool to Plasma Membrane in Rat Adipocytes , 1991, Diabetes.

[141]  D. Simonson,et al.  Effects of glyburide on in vivo insulin-mediated glucose disposal. , 1990, The American journal of medicine.

[142]  R. Taylor,et al.  Does Suppression of Postprandial Blood Glucose Excursions by the α-Glucosidase Inhibitor Miglitol Improve Insulin Sensitivity in Diet-Treated Type II Diabetic Patients? , 1996, Diabetes Care.

[143]  H. Lebovitz.  alpha-Glucosidase inhibitors. , 1997, Endocrinology and metabolism clinics of North America.

[144]  J. Clapham,et al.  Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats , 1998, Diabetes.

[145]  R. Henry,et al.  Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial , 1993, Diabetes Care.

[146]  J. Beavo,et al.  Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. , 1998, The Journal of clinical investigation.

[147]  G. Shulman,et al.  The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. , 1991, Metabolism: clinical and experimental.

[148]  H. Reinauer,et al.  Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[149]  G. Reaven,et al.  Further Evidence for a Central Role of Adipose Tissue in the Antihyperglycemic Effect of Metformin , 1998, Diabetes Care.

[150]  J. Buse,et al.  Troglitazone Use in Insulin-Treated Type 2 Diabetic Patients , 1998, Diabetes Care.

[151]  N. Nurjhan,et al.  Fat metabolism in human obesity. , 1994, The American journal of physiology.

[152]  L. Groop,et al.  Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy? , 1991, Diabete & metabolisme.

[153]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.

[154]  R. DeFronzo.  The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[155]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[156]  L. S. Hermann,et al.  Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. , 1991, Diabete & metabolisme.

[157]  L. Groop,et al.  UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations , 1996, Diabetologia.

[158]  A. Golay,et al.  Metformin treatment leads to an increase in basal, but not insulin‐stimulated, glucose disposal in obese patients with impaired glucose tolerance , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[159]  K. Heidenreich,et al.  In vitro studies on the action of CS-045, a new antidiabetic agent. , 1990, Metabolism: clinical and experimental.

[160]  S. Ross,et al.  The Efficacy of Acarbose in the Treatment of Patients with NonInsulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial , 1994, Annals of Internal Medicine.

[161]  Sulfonylurea binding to adipocyte membranes and potentiation of insulin-stimulated hexose transport. , 1989, The Journal of biological chemistry.

[162]  B. Clarke,et al.  Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. , 1989, Diabete & metabolisme.

[163]  G. Dohm,et al.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. , 1987, The Journal of clinical investigation.

[164]  J. Lehmann,et al.  Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. , 1996, Molecular pharmacology.

[165]  K. Clément,et al.  A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction , 1998, Nature.

[166]  L. Mandarino,et al.  Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. , 1988, Metabolism: clinical and experimental.

[167]  R. Unger,et al.  Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats* , 1998, The Journal of Biological Chemistry.

[168]  J. Flier,et al.  Coordinate regulation of glucose transporter function, number, and gene expression by insulin and sulfonylureas in L6 rat skeletal muscle cells. , 1989, The Journal of clinical investigation.

[169]  Rene Devos,et al.  Identification and expression cloning of a leptin receptor, OB-R , 1995, Cell.

[170]  M. Papa,et al.  Sphingomyelinase and Ceramide Suppress Insulin-induced Tyrosine Phosphorylation of the Insulin Receptor Substrate-1 (*) , 1996, The Journal of Biological Chemistry.

[171]  R N Bergman,et al.  Estimation of Endogenous Glucose Production During Hyperinsulinemic-Euglycemic Glucose Clamps: Comparison of Unlabeled and Labeled Exogenous Glucose Infusates , 1987, Diabetes.

[172]  H. Yki-Järvinen,et al.  Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. , 1984, The Journal of clinical endocrinology and metabolism.

[173]  R. S. Spielman,et al.  A genome–wide search for human non–insulin–dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2 , 1996, Nature Genetics.

[174]  J. Auwerx,et al.  PPAR Tissue Distribution and Interactions with Other Hormone‐Signaling Pathways a , 1996, Annals of the New York Academy of Sciences.

[175]  H. Gin,et al.  Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. , 1989, Diabetes research and clinical practice.

[176]  G. Reaven,et al.  Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients , 1990, Diabetes Care.

[177]  R. Bellomo,et al.  In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. , 1991, ASAIO transactions.

[178]  L. Groop,et al.  Effect of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity. , 1992, The American journal of physiology.

[179]  U. Smith,et al.  Metformin and metoprolol CR treatment in non‐obese men , 1994, Journal of internal medicine.

[180]  C. Ricordi,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Leptin Suppression of Insulin Secretion and Gene Expression in Human Pancreatic Islets: Implications for the Development of Adipogenic Diabetes Me , 2022 .

[181]  D. Gagnon.  Contraction of the rat colon by sympathomimetic amines: effect of methysergide and 5-HT desensitization. , 1972, European journal of pharmacology.

[182]  J. Halter,et al.  The Effect of Chronic Sulfonylurea Therapy on Hepatic Glucose Production in Non-insulin-dependent Diabetes , 1982, Diabetes.

[183]  Y. Nakaya,et al.  Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. , 1998, Diabetes.

[184]  H. Franke,et al.  Ein neues antidiabetisches Prinzip , 1955 .

[185]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[186]  L. Groop,et al.  Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. , 1989, The Journal of clinical investigation.

[187]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[188]  M. Laakso,et al.  Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects. , 1988, Metabolism: clinical and experimental.

[189]  J. Olefsky,et al.  Acute effects of troglitazone on in vivo insulin action in normal rats. , 1995, Metabolism: clinical and experimental.

[190]  T. Yoshioka,et al.  Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. , 1991, Metabolism: clinical and experimental.

[191]  H. Yee,et al.  A Review of the Safety and Efficacy of Acarbose in Diabetes Mellitus , 1996, Pharmacotherapy.

[192]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[193]  B. Zinman,et al.  Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers , 1999, Journal of Human Genetics.

[194]  K. Silver,et al.  Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPARγ) Gene in Diabetic Caucasians: Identification of a Pro12Ala PPARγ2 Missense Mutation , 1997 .

[195]  H. Yki-Järvinen,et al.  Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus , 1999, Diabetologia.

[196]  N. Hotta,et al.  Long‐term Effect of Acarbose on Glycaemic Control in Non‐insulin‐dependent Diabetes Mellitus: A Placebo‐controlled Double‐blind Study , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[197]  T. Dornan,et al.  Double-Blind Evaluation of Efficacy and Tolerability of Metformin in NIDDM , 1991, Diabetes Care.

[198]  L. Groop,et al.  Effect of Glyburide on Glycemic Control, Insulin Requirement, and Glucose Metabolism in Insulin-Treated Diabetic Patients , 1987, Diabetes.

[199]  R. Rizza,et al.  Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. , 1986, The New England journal of medicine.

[200]  P. Loirat,et al.  Role of Metformin Accumulation in Metformin-Associated Lactic Acidosis , 1995, Diabetes Care.

[201]  C. Kahn,et al.  Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. , 1982, Science.

[202]  H. Horikoshi,et al.  Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. , 1989, Journal of medicinal chemistry.

[203]  R. DeFronzo,et al.  Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. , 1991, The Journal of clinical endocrinology and metabolism.

[204]  R. Kletzien,et al.  Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. , 1994, Molecular pharmacology.

[205]  J. Foley,et al.  Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus , 1992, Diabetes Care.

[206]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[207]  G. Müller,et al.  The Sulfonylurea Drug, Glimepiride, Stimulates Glucose Transport, Glucose Transporter Translocation, and Dephosphorylation in Insulin-Resistant Rat Adipocytes In Vitro , 1993, Diabetes.

[208]  M. Spengler,et al.  Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. , 1997, The American journal of medicine.

[209]  T. Erren,et al.  Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus. , 1990, Atherosclerosis.

[210]  C. Bailey,et al.  Glucose‐lowering effect of BTS 67 582 , 1997, British journal of pharmacology.

[211]  H. Shamoon,et al.  Erratum: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects (Diabetes (1996) 45 (659-666)) , 1996 .

[212]  S. Rich,et al.  New Susceptibility Locus for NIDDM Is Localized to Human Chromosome 20q , 1997, Diabetes.

[213]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[214]  J. Mclelland,et al.  Recovery from Metformin Overdose , 1985, Diabetic medicine : a journal of the British Diabetic Association.

[215]  P. Raskin,et al.  A Double-Masked Placebo-Controlled Trial Assessing Effects of Various Doses of BTS 67,582, a Novel Insulinotropic Agent, on Fasting Hyperglycemia in NIDDM Patients , 1997, Diabetes Care.

[216]  R. Farese,et al.  Sulfonylureas activate glucose transport and protein kinase C in rat adipocytes. , 1991, Metabolism: clinical and experimental.

[217]  A. Sato,et al.  Acarbose alone or in combination with ethanol potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen in rats , 1999, Hepatology.

[218]  G. Müller,et al.  Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride. , 1995, Endocrinology.

[219]  M. Laakso,et al.  The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data , 1998, Diabetes Care.

[220]  W. Steinke,et al.  Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs. , 1989, Arzneimittel-Forschung.

[221]  Simeon I. Taylor,et al.  Lilly Lecture: Molecular Mechanisms of Insulin Resistance: Lessons From Patients With Mutations in the Insulin-Receptor Gene , 1992, Diabetes.

[222]  M. Mittal,et al.  Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report , 2000, Annals of Internal Medicine.

[223]  B V Howard,et al.  Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. , 1984, The Journal of clinical investigation.

[224]  H. Ahr,et al.  Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. , 1989, Arzneimittel-Forschung.

[225]  T. Buchanan,et al.  Effect of Troglitazone on Insulin Sensitivity and Pancreatic β-Cell Function in Women at High Risk for NIDDM , 1996, Diabetes.

[226]  O. Pedersen,et al.  Insulin receptor substrate-2 amino acid polymorphisms are not associated with random type 2 diabetes among Caucasians. , 1998, Diabetes.

[227]  U. Panten,et al.  Sulfonylurea receptors and mechanism of sulfonylurea action. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[228]  H. Ginsberg,et al.  Effect of Insulin Therapy on Insulin Resistance in Type II Diabetic Subjects: Evidence for Heterogeneity , 1981, Diabetes.

[229]  L. Groop,et al.  Metabolic Consequences of Sustained Suppression of Free Fatty Acids by Acipimox in Patients With NIDDM , 1993, Diabetes.

[230]  D. Lockwood,et al.  In vitro effects of a sulfonylurea on insulin action in adipocytes. Potentiation of insulin-stimulated hexose transport. , 1981, The Journal of clinical investigation.

[231]  L. Groop,et al.  Obesity and insulin resistance in humans: a dose-response study. , 1990, Metabolism: clinical and experimental.

[232]  C. Bailey,et al.  11 Treatment—metformin , 1988 .

[233]  H. Yki-Järvinen,et al.  Effect of exercise on insulin binding and glucose transport in adipocytes of normal humans. , 1987, Journal of applied physiology.

[234]  H. Beck-Nielsen,et al.  Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. , 1989, Acta endocrinologica.

[235]  J. Idle,et al.  Influence of oxidation polymorphism on phenformin kinetics and dynamics , 1983, Clinical pharmacology and therapeutics.

[236]  H. Nawata,et al.  Effects of a New Oral Hypoglycaemic Agent (CS‐045) on Metabolic Abnormalities and Insulin Resistance in Type 2 Diabetes , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[237]  J. F. Caro,et al.  Effects of glyburide on carbohydrate metabolism and insulin action in the liver. , 1990, The American journal of medicine.

[238]  S. O’Rahilly.  Human physiology: Life without leptin , 1998, Nature.

[239]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[240]  L. Ryysy,et al.  Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[241]  D. Lockwood,et al.  Sulfonylurea effects on target tissues for insulin. , 1984, Diabetes care.

[242]  U. Smith,et al.  Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors , 1991, Journal of internal medicine.

[243]  J. Olefsky,et al.  Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects , 1992, Diabetes Care.

[244]  Lebovitz He.  Cellular loci of sulfonylurea actions. , 1984 .

[245]  G. Lienhard,et al.  A Novel 160-kDa Phosphotyrosine Protein in Insulin-treated Embryonic Kidney Cells Is a New Member of the Insulin Receptor Substrate Family* , 1997, The Journal of Biological Chemistry.

[246]  H. Gin,et al.  Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. , 1985, Metabolism: clinical and experimental.

[247]  M. Ehm,et al.  An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. , 1998, American journal of human genetics.

[248]  J. Zierath,et al.  Insulin Receptor Substrate-1 Phosphorylation and Phosphatidylinositol 3-Kinase Activity in Skeletal Muscle From NIDDM Subjects After In Vivo Insulin Stimulation , 1997, Diabetes.

[249]  A. Tiengo,et al.  Hepatic sensitivity to insulin: effects of sulfonylurea drugs. , 1991, The American journal of medicine.

[250]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[251]  H. Häring,et al.  Insulin signal transduction: possible mechanisms for insulin resistance. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[252]  M. Carrascosa,et al.  Acarbose-induced acute severe hepatotoxicity , 1997, The Lancet.

[253]  J. Balfour,et al.  Glimepiride , 1998, Drugs.

[254]  E. Jéquier,et al.  Impairment of glucose disposal by infusion of triglycerides in humans: role of glycemia. , 1989, The American journal of physiology.

[255]  T. Leff,et al.  Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. , 1999, Diabetes.

[256]  H. Yki-Järvinen,et al.  Inhibition of Lipolysis Decreases Lipid Oxidation and Gluconeogenesis From Lactate But Not Fasting Hyperglycemia or Total Hepatic Glucose Production in NIDDM , 1993, Diabetes.

[257]  J. Olefsky,et al.  Insulin-Receptor Autophosphorylation and Endogenous Substrate Phosphorylation in Human Adipocytes From Control, Obese, and NIDDM Subjects , 1990, Diabetes.

[258]  R G Smith,et al.  Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. , 1999, Science.

[259]  B. Cohen,et al.  Modulation of Insulin Activities by Leptin , 1996, Science.

[260]  D. McTavish,et al.  Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus. , 1993, Drugs.

[261]  P. Grant,et al.  Metformin Causes a Reduction in Basal and Post‐venous Occlusion Plasminogen Activator Inhibitor‐1 in Type 2 Diabetic Patients , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[262]  T. Koschinsky,et al.  Oral antidiabetic combination therapy with sulphonylureas and metformin. , 1991, Diabete & metabolisme.

[263]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[264]  M. Igarashi,et al.  Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. , 1993, Endocrine journal.

[265]  D. Kelley,et al.  Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.

[266]  H. Wildberger,et al.  LONG‐TERM STUDIES OF THE SULFONYLUREAS IN TOTALLY DEPANCREATIZED DOGS , 1957, Annals of the New York Academy of Sciences.

[267]  Y. Ueki,et al.  Effects of Voglibose on Glycemic Excursions, Insulin Secretion, and Insulin Sensitivity in Non-lnsulin-ireated NIDDM Patients , 1998, Diabetes Care.

[268]  L. S. Hermann.  Biguanides and Sulfonylureas as Combination Therapy in NIDDM , 1990, Diabetes Care.

[269]  T. Hansen,et al.  Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus , 1993, The Lancet.

[270]  M. White,et al.  A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus. , 1989, The Journal of biological chemistry.

[271]  S. Jacob,et al.  Insulin action and secretion in healthy, glucose tolerant first degree relatives of patients with type 2 diabetes mellitus. Influence of body weight. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[272]  T. Jenssen,et al.  Contribution of Abnormal Muscle and Liver Glucose Metabolism to Postprandial Hyperglycemia in NIDDM , 1990, Diabetes.

[273]  D R Hadden,et al.  Beta‐cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10‐year follow‐up of the Belfast Diet Study , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[274]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[275]  Y. Hara,et al.  Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. , 1996, Metabolism: clinical and experimental.

[276]  G. Schernthaner,et al.  The Efficacy and Safety of Miglitol Therapy Compared With Glibenclamide in Patients With NIDDM Inadequately Controlled by Diet Alone , 1997, Diabetes Care.

[277]  R. Rosskamp.  Safety aspects of oral hypoglycaemic agents , 1996, Diabetologia.

[278]  G. Bray,et al.  Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. , 1995, The American journal of medicine.

[279]  Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. , 1996, Endocrinology.

[280]  R. Farese,et al.  Protein Kinase C-ζ as a Downstream Effector of Phosphatidylinositol 3-Kinase during Insulin Stimulation in Rat Adipocytes , 1997, The Journal of Biological Chemistry.

[281]  G. Reaven,et al.  Effect of Sulfonylurea Treatment on In Vivo Insulin Secretion and Action in Patients With Non-insulin-dependent Diabetes Mellitus , 1982, Diabetes.

[282]  E. Draeger,et al.  Clinical profile of the novel sulphonylurea glimepiride. , 1996, Diabetes research and clinical practice.

[283]  J. Morley,et al.  Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. , 1998, Obesity research.

[284]  J Downward,et al.  PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. , 1997, Trends in biochemical sciences.

[285]  M. Emoto,et al.  CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes. , 1994, European journal of pharmacology.

[286]  W. Malaisse,et al.  Mechanisms of Sulfonylurea-lnduced Insulin Release , 1990, Diabetes Care.

[287]  C. Bailey,et al.  Accumulation of metformin by tissues of the normal and diabetic mouse. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[288]  R. Marfella,et al.  Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women , 1993, Diabetes Care.

[289]  C. Kahn,et al.  Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. , 1995, The Journal of clinical endocrinology and metabolism.

[290]  K. Kosaka,et al.  Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[291]  R. Smith,et al.  Effects of the sulfonylureas on muscle glucose homeostasis. , 1990, The American journal of medicine.

[292]  L. Groop,et al.  Metformin Normalizes Nonoxidative Glucose Metabolism in Insulin-Resistant Normoglycemic First-Degree Relatives of Patients With NIDDM , 1992, Diabetes.

[293]  R. DeFronzo,et al.  Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. , 1996, The Journal of clinical endocrinology and metabolism.

[294]  P. J. Randle,et al.  Glucose fatty acid interactions and the regulation of glucose disposal , 1994, Journal of cellular biochemistry.

[295]  C. Kahn,et al.  Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. , 1991, The Journal of clinical investigation.

[296]  S. Josephkutty,et al.  Comparison of Tolbutamide and Metformin in Elderly Diabetic Patients , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[297]  P. Hespel,et al.  Important Role of Insulin and Flow in Stimulating Glucose Uptake in Contracting Skeletal Muscle , 1995, Diabetes.

[298]  A. Swislocki,et al.  Glucose tolerance and blood pressure are improved in the spontaneously hypertensive rat by ethyl-2-(6-(4-chlorophenoxy)-hexyl)oxirane-2-carboxylate (etomoxir), an inhibitor of fatty acid oxidation. , 1994, American journal of hypertension.

[299]  A. Harrower.  Pharmacokinetics of Oral Antihyperglycaemic Agents in Patients with Renal Insufficiency , 1996, Clinical pharmacokinetics.

[300]  L. Teboul,et al.  Thiazolidinediones and Fatty Acids Convert Myogenic Cells into Adipose-like Cells (*) , 1995, The Journal of Biological Chemistry.

[301]  J. Olefsky.  Insulin resistance and the pathogenesis of non-insulin dependent diabetes mellitus: cellular and molecular mechanisms. , 1993, Advances in experimental medicine and biology.

[302]  B. Spiegelman,et al.  Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. , 1994, Endocrinology.

[303]  E. Volpi,et al.  Evidence of Increased Systemic Glucose Production and Gluconeogenesis in an Early Stage of NIDDM , 1997, Diabetes.

[304]  H. Häring,et al.  Troglitazone Prevents Glucose-Induced Insulin Resistance of Insulin Receptor in Rat-1 Fibroblasts , 1994, Diabetes.

[305]  J. Buse,et al.  The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. , 1998, Clinical therapeutics.

[306]  R. Jones,et al.  Evaluation of BTS 67 582, a novel antidiabetic agent, in normal and diabetic rats , 1997, British journal of pharmacology.

[307]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[308]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[309]  T. Asano,et al.  Direct Stimulation of Basal Insulin Secretion by Physiological Concentrations of Leptin in Pancreatic β Cells. , 1997, Endocrinology.

[310]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[311]  D. Tschoepe,et al.  Heart disease in diabetes mellitus: a challenge for early diagnosis and intervention. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[312]  H. Graf,et al.  Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. , 1986, Diabete & metabolisme.

[313]  R. DeFronzo,et al.  Effect of Physical Training on Insulin Action in Obesity , 1987, Diabetes.

[314]  J. A. Scarlett,et al.  Insulin Treatment Reverses the Insulin Resistance of Type II Diabetes Mellitus , 1982, Diabetes Care.

[315]  R. Rizza,et al.  Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. , 1992, The New England journal of medicine.

[316]  J. Olefsky,et al.  The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. , 1984, Diabetes care.

[317]  D. Lockwood,et al.  Effects of sulfonylureas on the actions of insulin and insulin-mimickers: potentiation of stimulated hexose transport in adipocytes. , 1984, European journal of pharmacology.

[318]  G. Biolo,et al.  Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes. , 1994, The Journal of clinical endocrinology and metabolism.

[319]  J. G. Alvarez,et al.  Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.

[320]  D. Johnston,et al.  The Effects of Metformin on Glycemic Control and Serum Lipids in Insulin-Treated NIDDM Patients With Suboptimal Metabolic Control , 1998, Diabetes Care.

[321]  T. Yagi,et al.  Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 , 1994, Nature.

[322]  P. O’Connell,et al.  Evidence for a Major Gene for Type II Diabetes and Linkage Analyses With Selected Candidate Genes in Mexican-Americans , 1996, Diabetes.

[323]  T. Kuhn.  The second generation oral sulfonylureas: glyburide and glipizide. , 1988, American pharmacy.

[324]  P. Grant.  The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes , 1996, Diabetes Care.

[325]  G. Reaven,et al.  Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. , 1992, The Journal of clinical endocrinology and metabolism.

[326]  G. Müller,et al.  Leptin Impairs Metabolic Actions of Insulin in Isolated Rat Adipocytes* , 1997, The Journal of Biological Chemistry.

[327]  M. Stumvoll,et al.  Renal glucose production and utilization: new aspects in humans , 1997, Diabetologia.

[328]  J. McGill,et al.  Reduction of Glycosylated Hemoglobin and Postprandial Hyperglycemia by Acarbose in Patients With NIDDM: A placebo-controlled dose-comparison study , 1995, Diabetes Care.

[329]  A. Ullrich,et al.  Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. , 1996, The Journal of clinical investigation.

[330]  J. McNeill,et al.  Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. , 1992, Journal of medicinal chemistry.

[331]  D. Lockwood,et al.  Impaired Glucose Tolerance is Normalized by Treatment With the Thiazolidinedione Troglitazone , 1997, Diabetes Care.

[332]  B. D. Prendergast.  Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. , 1984, Clinical pharmacy.

[333]  M. Ehm,et al.  An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. , 1998, The Journal of clinical investigation.

[334]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[335]  G. Dailey,et al.  Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. , 1995, JAMA.

[336]  C. Bogardus,et al.  Variant in the regulatory subunit of phosphatidylinositol 3-kinase (p85alpha): preliminary evidence indicates a potential role of this variant in the acute insulin response and type 2 diabetes in Pima women. , 1998, Diabetes.

[337]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[338]  Clark He,et al.  The Effect of Glimepiride on Pancreatic β-Cell Function Under Hyperglycaemic Clamp and Hyperinsulinaemic, Euglycaemic Clamp Conditions in Non-Insulin-Dependent Diabetes Mellitus , 1996 .

[339]  L. Tartaglia,et al.  Leptin and OB-R: body weight regulation by a cytokine receptor. , 1996, Cytokine & growth factor reviews.

[340]  A. Tiengo,et al.  Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. , 1991, Diabete & metabolisme.

[341]  C. Sum,et al.  The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. , 1993, Metabolism: clinical and experimental.

[342]  T. Hansen,et al.  Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1 , 1995, The Lancet.

[343]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[344]  U. Panten,et al.  Pancreatic and Extrapancreatic Sulfonylurea Receptors , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[345]  M. Ishii,et al.  Acarbose-induced generalised erythema multiforme , 1999, The Lancet.

[346]  K. Clément,et al.  A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10 , 1998, Nature Genetics.

[347]  F. Collins,et al.  Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[348]  T. Hansen,et al.  Identification of a Common Amino Acid Polymorphism in the p85α Regulatory Subunit of Phosphatidylinositol 3-Kinase: Effects on Glucose Disappearance Constant, Glucose Effectiveness, and the Insulin Sensitivity Index , 1997, Diabetes.

[349]  O. Pedersen,et al.  A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. , 1996, The Journal of clinical investigation.

[350]  J. Feldman,et al.  The pharmacology of sulfonylureas. , 1981, The American journal of medicine.

[351]  P. Winocour,et al.  Placebo‐controlled Trial of the Effects of Guar Gum and Metformin on Fasting Blood Glucose and Serum Lipids in Obese, Type 2 Diabetic Patients , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[352]  H. Maegawa,et al.  Impaired Autophosphorylation of Insulin Receptors From Abdominal Skeletal Muscles in Nonobese Subjects With NIDDM , 1991, Diabetes.

[353]  R. Holman,et al.  A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) , 1999, Diabetes care.

[354]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[355]  G. Reaven,et al.  Effect of Acarbose on Carbohydrate and Lipid Metabolism in NIDDM Patients Poorly Controlled by Sulfonylureas , 1990, Diabetes Care.

[356]  Y. Matsuzawa,et al.  Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase , 1999, Nature Genetics.

[357]  J. Flier,et al.  Insulin resistance--mechanisms, syndromes, and implications. , 1991, The New England journal of medicine.

[358]  J. Olefsky,et al.  Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. , 1994, The Journal of clinical endocrinology and metabolism.

[359]  M. Uusitupa,et al.  Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. , 1990, Annals of medicine.

[360]  S. Hafiz.  Why? Which? and how? , 1990, JPMA. The Journal of the Pakistan Medical Association.

[361]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[362]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[363]  M. Muggeo,et al.  Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. , 2000, The Journal of clinical endocrinology and metabolism.

[364]  M. Stumvoll,et al.  Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. , 1998, The Journal of clinical investigation.

[365]  P. Lefebvre,et al.  Short Administration of Metformin Improves Insulin Sensitivity in Android Obese Subjects with Impaired Glucose Tolerance , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[366]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[367]  M. Standaert,et al.  Direct Effects of Sulfonylurea Agents on Glucose Transport in the BC3H-1 Myocyte , 1987, Diabetes.

[368]  M. Inaba,et al.  Relationship Between Gastric Emptying and an α-Glucosidase Inhibitor Effect on Postprandial Hyperglycemia in NIDDM Patients , 1997, Diabetes Care.

[369]  K. Siddle,et al.  Differential Regulation of Phosphoinositide 3-Kinase Adapter Subunit Variants by Insulin in Human Skeletal Muscle* , 1997, The Journal of Biological Chemistry.

[370]  K. Bergis,et al.  Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. , 1991, Diabete & metabolisme.

[371]  R. Campbell,et al.  Acarbose: Its Role in the Treatment of Diabetes Mellitus , 1996, The Annals of pharmacotherapy.

[372]  P. Raskin,et al.  Rosiglitazone (RSG) Improves Glycemic Control in Poorly Controlled, Insulin-Treated Type 2 Diabetes (T2D) , 1999 .

[373]  H. Häring,et al.  The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects , 1999, Diabetologia.

[374]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[375]  G. Mertes.  Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. , 1998, Diabetes research and clinical practice.

[376]  D. Kelley,et al.  Chronic Treatment of African-American Type 2 Diabetic Patients With β-Glucosidase Inhibition , 1998, Diabetes Care.

[377]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[378]  S. Clissold,et al.  Acarbose , 2022, Drugs.

[379]  T. Buchanan,et al.  Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus , 1998, Annals of Internal Medicine.

[380]  D. Jakubowicz,et al.  Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. , 1998, The New England journal of medicine.

[381]  M. Stumvoll,et al.  Multiple sites of insulin resistance: muscle, liver and adipose tissue. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[382]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[383]  R R Wing,et al.  Long-term effects of modest weight loss in type II diabetic patients. , 1987, Archives of internal medicine.

[384]  H. Shamoon,et al.  Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.

[385]  J. Habener,et al.  Leptin Suppression of Insulin Secretion by the Activation of ATP-Sensitive K+ Channels in Pancreatic β-Cells , 1997, Diabetes.

[386]  D. York,et al.  Effects of Leptin on Insulin Secretion From Isolated Rat Pancreatic Islets , 1998, Diabetes.

[387]  D. Everitt,et al.  Rosiglitazone and Hepatic Failure , 2000, Annals of Internal Medicine.

[388]  M. White,et al.  Requirement of protein kinase C zeta for stimulation of protein synthesis by insulin , 1997, Molecular and cellular biology.

[389]  G. Chatellier,et al.  [Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics]. , 1990, Diabete & metabolisme.

[390]  M. Spengler,et al.  Efficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen Study , 1994, Diabetes Care.

[391]  M. Mori,et al.  Leptin Stimulates Insulin Secretion and Synthesis in HIT-T 15 Cells , 1997, Peptides.

[392]  J. Olefsky,et al.  Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro. , 1983, The American journal of medicine.

[393]  H. Iwatsuka,et al.  Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent , 1983, Diabetes.

[394]  J. Yudkin,et al.  Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups , 1993, Diabetes Care.

[395]  A. Newton,et al.  Regulation of protein kinase C ζ by PI 3-kinase and PDK-1 , 1998, Current Biology.

[396]  J. Zierath,et al.  Insulin-Stimulated Akt Kinase Activity Is Reduced in Skeletal Muscle From NIDDM Subjects , 1998, Diabetes.

[397]  C. Bogardus,et al.  Genome-wide scan for CAG/CTG repeat expansions in Pimas with early onset of type 2 diabetes mellitus. , 1999, Molecular genetics and metabolism.

[398]  C. Kahn,et al.  Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene , 1994, Nature.

[399]  E. Ferrannini,et al.  Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production , 1994, Diabetes.

[400]  Roy Taylor,et al.  Effects of an Engineered Human Anti–TNF-α Antibody (CDP571) on Insulin Sensitivity and Glycemic Control in Patients With NIDDM , 1996, Diabetes.

[401]  Ž. Metelko,et al.  Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment , 1996, Diabetologia.

[402]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[403]  C. J. Bailey,et al.  Metformin Revisited: Its Actions and Indications for Use , 1988, Diabetic medicine : a journal of the British Diabetic Association.

[404]  T. Hansen,et al.  Prevalence of a Polymorphism of the Phosphatidylinositol 3-Kinase p85α Regulatory Subunit (Codon 326Met→ile) in Japanese NIDDM Patients , 1997, Diabetes Care.

[405]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[406]  E. Ferrannini.  Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. , 1998, Endocrine reviews.

[407]  Philip R. Cohen,et al.  Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. , 1998, Science.

[408]  Campbell Iw.  Metformin and the sulphonylureas: the comparative risk. , 1985 .

[409]  G Sonnenberg,et al.  Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. , 1988, The Journal of clinical investigation.

[410]  C Cobelli,et al.  Effect of insulin on the distribution and disposition of glucose in man. , 1985, The Journal of clinical investigation.

[411]  M. Leppert,et al.  A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. , 1999, Diabetes.

[412]  F. Ashcroft.  Mechanisms of the Glycaemic Effects of Sulfonylureas , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[413]  P. Lönnroth,et al.  Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. , 1983, British medical journal.

[414]  R. Parrilla,et al.  Control of hepatic gluconeogenesis: role of fatty acid oxidation. , 1989, Archives of biochemistry and biophysics.

[415]  C. Kahn,et al.  Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells , 1985, Nature.

[416]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[417]  K. Siddle,et al.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. , 1998, The Biochemical journal.

[418]  M. McCarthy,et al.  Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families , 1996, Nature Genetics.

[419]  A. Pontiroli,et al.  Sulfonylureas Enhance In Vivo the Effectiveness of Insulin in Type 1 (Insulin Dependent) Diabetes Mellitus , 1984, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[420]  B. Neuschwander‐Tetri,et al.  Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report , 1998, Annals of Internal Medicine.

[421]  H. Klein,et al.  Elevation of Serum Insulin Concentration During Euglycemic Hyperinsulinemic Clamp Studies Leads to Similar Activation of Insulin Receptor Kinase in Skeletal Muscle of Subjects With and Without NIDDM , 1995, Diabetes.

[422]  L. Groop,et al.  Interactions between glucose and FFA metabolism in man. , 1996, Diabetes/metabolism reviews.

[423]  J. Beckmann,et al.  A susceptibility locus for early-onset non-insulin dependent (type 2) diabetes mellitus maps to chromosome 20q, proximal to the phosphoenolpyruvate carboxykinase gene. , 1997, Human molecular genetics.

[424]  J. Rosenstock,et al.  Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients , 1996, Diabetes Care.

[425]  G. Müller,et al.  The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels , 1995 .

[426]  P. O'Connell,et al.  Evidence for linkage of regions on chromosomes 6 and 11 to plasma glucose concentrations in Mexican Americans. , 1996, Genome research.

[427]  L. Aguilar-Bryan,et al.  Molecular mechanisms of action of glyburide on the beta cell. , 1990, The American journal of medicine.

[428]  H. Lebovitz,et al.  Sulfonylureas Why, Which, and How? , 1990, Diabetes Care.

[429]  J. Auwerx,et al.  Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. , 1996, The Journal of clinical investigation.

[430]  J. Schneider.  An overview of the safety and tolerance of glimepiride. , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[431]  L. Goodyear,et al.  Exercise, glucose transport, and insulin sensitivity. , 1998, Annual review of medicine.